Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026)
Argenx Se's (ARGX) quarterly Income from Continuing Operations came in at 482000000.0 in Q2 2026, up 167.93% YoY from 179899000.0 in Q2 2025, and up 27.51% on a QoQ basis from 378000000.0 in Q1 2026.
Argenx Se (ARGX) Income from Continuing Operations (2016 - 2026) Analysis & Trends
Argenx Se (ARGX) has 11 years of Income from Continuing Operations data on file, last reported at 482000000.0 in Q2 2026.
- Quarterly Income from Continuing Operations rose 167.93% year-over-year to 482000000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was 1649347000.0 (up 180.91% YoY) and the FY2025 annual result came in at 1292035000.0, up 55.1% from the prior year.
- Income from Continuing Operations rose to 482000000.0 in Q2 2026, from 378000000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 482000000.0 in Q2 2026 to a low of 244141000.0 in Q1 2022.
- A 5-year average of 62468611.11 and a median of 28120500.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 1451.46% — and 2025, when it soared 1299.09%.
- Tracing ARGX's Income from Continuing Operations over 5 years: stood at 41238000.0 in 2022, then sank by 48.35% to 61178000.0 in 2023, then soared by 237.06% to 83851000.0 in 2024, then soared by 380.97% to 403294000.0 in 2025, then advanced by 19.52% to 482000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 482000000.0 (Q2 2026), 378000000.0 (Q1 2026), and 403294000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -290.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 482.00 Mn |
| Mar 31, 2026 | 378.00 Mn |
| Dec 31, 2025 | 403.29 Mn |
| Sep 30, 2025 | 386.05 Mn |
| Jun 30, 2025 | 179.90 Mn |
| Mar 31, 2025 | 235.36 Mn |
| Dec 31, 2024 | 83.85 Mn |
| Sep 30, 2024 | 88.02 Mn |
| Jun 30, 2024 | -15.00 Mn |
| Mar 31, 2024 | -74.35 Mn |
| Dec 31, 2023 | -61.18 Mn |
| Sep 30, 2023 | -83.28 Mn |
| Jun 30, 2023 | -83.86 Mn |
| Mar 31, 2023 | -76.18 Mn |
| Dec 31, 2022 | -41.24 Mn |
| Sep 30, 2022 | -241.02 Mn |
| Jun 30, 2022 | -191.80 Mn |
| Mar 31, 2022 | -244.14 Mn |
| Dec 31, 2021 | 244.88 Mn |
| Sep 30, 2021 | -230.87 Mn |